Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Nurix Therapeutics's total assets was $1.20B at Aug 31, 2026. For fiscal 2025 it was $688.14M, up 2.8% from the year before. The highest annual figure on record is $688.14M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $688.14M | +2.8% |
| FY2024 | Nov 30, 2024 | $669.34M | +88.2% |
| FY2023 | Nov 30, 2023 | $355.60M | -14.7% |
| FY2022 | Nov 30, 2022 | $416.76M | -12.6% |
| FY2021 | Nov 30, 2021 | $476.77M | +20.3% |
| FY2020 | Nov 30, 2020 | $396.34M | +799.8% |
| FY2019 | Nov 30, 2019 | $44.05M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $1.20B | +128.8% |
| Q2 FY2026CQ2 2026 | May 31, 2026 | $535.54M | -9.5% |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | $636.13M | +3.4% |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | $688.14M | +2.8% |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | $522.47M | +1.7% |
| Q2 FY2025CQ2 2025 | May 31, 2025 | $591.56M | +15.8% |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | $615.04M | +96.7% |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | $669.34M | +88.2% |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | $513.60M | +66.6% |
| Q2 FY2024CQ2 2024 | May 31, 2024 | $511.03M | +45.7% |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | $312.67M | -15.5% |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | $355.60M | -14.7% |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | $308.20M | -32.9% |
| Q2 FY2023CQ2 2023 | May 31, 2023 | $350.62M | -11.1% |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | $370.15M | -15.4% |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | $416.76M | -12.6% |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | $459.34M | -6.8% |
| Q2 FY2022CQ2 2022 | May 31, 2022 | $394.31M | -23.9% |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | $437.72M | +10.4% |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | $476.77M | +20.3% |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | $493.07M | +19.7% |
| Q2 FY2021CQ2 2021 | May 31, 2021 | $517.98M | +1075.9% |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | $396.66M | – |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | $396.34M | – |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | $411.87M | – |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | $44.05M | – |
See a number that looks wrong?